ZHAO Ben 赵孝斌

Dr Ben Zhao

  • Founder, CEO, Zhejiang Haichang Biotech Co., Ltd.

Ben Zhao is founder and CEO of Zhejiang Haichang Biotech Co., Ltd. (HCBio). Prior to HCBio, Dr. Zhao is a CMC reviewer and GMP inspector specialized in complex drugs at the US FDA. In 2014, he founded HCBio devoted to developing high-quality liposomal drugs with rational design. Previously, Dr. Zhao was a group leader in developing small interfering RNA (siRNA) at Abbott Laboratories. In China, he developed the first generic liposomal doxorubicin (Libaoduo®) in 2008. Dr. Zhao is an inventor of 12 patents and has published over twenty peer reviewed articles. He also serves as an Expert Working Group (EWG) member for ICH, and an Advisory Board member for the NSF Nanotechnology center. Dr. Zhao was trained as a medical doctor at Norman Bethune University of Medical Sciences and received a Ph.D. degree from the Ohio State University.